基于单核苷酸多态性检测的无创产前筛查发现额外单倍型时对胎儿三倍体的鉴别诊断与临床管理
研究回顾2017年9月至2019年3月共515804例接受基于单核苷酸多态性(SNP)的无创产前检测(NIPT)的孕妇,其中1005例出现额外单倍型(1/513)。773例有妊娠结局:11%确诊或疑似三倍体,65%为消失双胎,10%为妊娠丢失;三倍体病例中23/27(85%)为双雄来源。作者建议对额外单倍型行超声检查以确认存活、评估双胎并发现三倍体相关表现。
要点
- SNP-based NIPT出现额外单倍型时,11%预测三倍体。
- 额外单倍型最常见原因为消失双胎(65%)。
- 作者建议超声确认存活、评估双胎并发现三倍体表现。
核心结论
- 基于SNP的NIPT检测到额外单倍型时,对三倍体的预测值为11%。
- 作者建议对额外单倍型结果行超声检查以确认存活、评估双胎(存活或消失)并发现与三倍体一致的表现。
- 结合病史、血清筛查和超声可减少确诊三倍体所需的绒毛膜取样或羊膜腔穿刺次数。
研究设计与样本
- 研究回顾了2017年9月至2019年3月共515804例接受NIPT的孕妇,所有出现额外单倍型的结果均被复核,排除已知存活双胎和消失双胎妊娠后,对阳性病例追查妊娠结局。
- 共1005例结果出现额外单倍型(1/513),其中773例获得妊娠结局信息。
主要发现
- 773例有结局的病例中,11%确诊或疑似三倍体,65%为消失双胎,10%为妊娠丢失。
- 罕见原因包括完全性葡萄胎、嵌合体、未告知的供卵妊娠、母体器官移植及1例母体肿瘤。
- 在检出并独立确认的三倍体病例中,23/27(85%)为双雄来源。
临床怎么用
- 作者建议对出现额外单倍型的NIPT结果行超声检查,以确认存活、评估双胎(存活或消失)并发现与三倍体一致的表现。
- 作者认为结合病史、血清筛查和超声可减少确诊三倍体所需的绒毛膜取样或羊膜腔穿刺次数。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An extra haplotype is infrequently encountered in single nucleotide polymorphism(SNP)-based non-invasive prenatal testing (NIPT) and is usually attributed to an undetected twin or triploidy. We reviewed a large series to establish relative frequencies of these outcomes and identify alternative causes. METHODS: In 515,804 women receiving NIPT from September 2017 through March 2019, all results with an extra haplotype were reviewed. Known viable and vanished twin pregnancies were excluded. For positive cases, pregnancy outcome information was sought. RESULTS: Of 1005 results with an extra haplotype (1 in 513), pregnancy outcome was available for 773 cases: 11% were confirmed or suspected triploidy; 65% to vanished twin; 10% with pregnancy loss. Rare explanations included complete mole, chimera, undisclosed donor egg pregnancy, maternal organ transplant and one instance of maternal neoplasm. Among triploid cases that were detected and independently confirmed, 23/27 (85%) were diandric. CONCLUSION: SNP-based NIPT, with detection of an extra haplotype, is 11% predictive of triploidy. For results with an extra haplotype, ultrasound is recommended to establish viability, evaluate for twins (viable or vanished), and detect findings consistent with triploidy. Review of patient history, serum screening, and ultrasound will reduce the number of CVS or amniocenteses necessary to confirm a diagnosis of triploidy.
引用
- Kantor V, Jelsema R, Xu W, et al. Non-invasive prenatal screening for fetal triploidy using single nucleotide polymorphism-based testing: Differential diagnosis and clinical management in cases showing an extra haplotype. Prenat Diagn. 2022. PMID: 35574995. doi:10.1002/pd.6169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。